Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Surg Oncol Clin N Am. 2010 Jan;19(1):101–113. doi: 10.1016/j.soc.2009.09.004
# Patients
Randomized		 Study Groups Stratification Significance
Demonstrated		 % Change
Identified in Trial
946 400 mg imatinib once daily n = 473

400 mg imatinib twice daily n = 473		 None 400 mg imatinib daily results in partial response of disease while a dose of 400 mg imatinib twice daily improves progression-free survival Progression-free survival: Hazard ratio 0.82 (95% CI 0.69–0.98, p = 0.026)